EMAIL DETAILS

Hey Steve,

Absolutely. I will ping Mary tomorrow and try and set something up. She's
a rock star - founded Accretive Health off the back of napkin 11 years ago.

Eugene is an Entrepreneur in Residence at Artiman - a "white space" venture
fund founded by Amit Shah. Artiman has four life sciences companies in the
current portfolio: CardioDx, CellMax, Cellworks and Core Diagnostics. I am
in conversations with Amit on another topic and will connect SUH once it
concludes.

Will be in touch.

Best,

Neil


Neil Callahan
Rosemont Seneca Partners
401 Greenwich Street, Suite 300
New York, New York 10013
917-945-9516 (m)
866-749-8879 (f)
www.rosemontsenecatech.com
Confidentiality Warning: This e-mail contains information intended only for
the use of the individual or entity named above. If the reader of this
e-mail is not the intended recipient or the employee or agent responsible
for delivering it to the intended recipient, any dissemination, publication
or copying of this e-mail is strictly prohibited. The sender does not accept
any responsibility for any loss, disruption or damage to your data or
computer system that may occur while using data contained in, or transmitted
with, this e-mail.If you have received this e-mail in error, please
immediately notify us by return e-mail. Thank you


-----Original Message-----
From: Steven Krein [mailto:steve@startuphealth.com]
Sent: Thursday, February 13, 2014 8:29 PM
To: <ncallahan@rosemontseneca.com>
Cc: Howard Krein; Unity Stoakes; Hunter Biden
Subject: Re: Great meeting you

Neil,

Thanks for spending the evening with us. I hope you enjoyed yourself and
glad you hit it off with Mike.

I wanted to follow up on your suggestion to introduce us to Mary Tolan and
Eugene Lee. Mary sounds like she'd be a valuable addition to our investor
community...we'd be happy to make room in the original Fund for both her and
Eugene (or any friend of Rosemont you think would be valuable, for that
matter). Please let me know the best way to make this happen.

Also, Biodirection looks like a great company. I'd love to connect Brian
with Adam from Cerora when the timing is right. In fact, Brian would be a
great addition to our community of Healthcare Transformers.

Thanks and look forward to next steps.

steve
-------
Steven Krein
CEO
StartUp Health
steve@startuphealth.com
917-903-4288
@stevenkrein


On Thu, Feb 13, 2014 at 2:42 PM, Neil Callahan (Rosemont Seneca)
<ncallahan@rosemontseneca.com> wrote:
> Hey guys,
>
>
>
> It was great seeing you all yesterday. Hopefully the LaGuardia hotels
> are well stocked for today! We easily have gotten 14 inches of snow
> so far today in New Jersey and will get another 3-5 inches this
> evening as the rain changes back to snow.
>
>
>
> A great dinner - the SUH team is doing different and needed work
> within the industry. You've made awesome progress.
>
>
>
> The concussion detection company that I mentioned last night is called
> BioDirection - http://www.biodirection.com/about-us/
>
>
>
> They are in the middle of fund raise - their main focus right now is
> to impact ER protocols and to get trail in trauma centers as well as
> working on their contract manufacturing supply chain. They feel
> pretty good about the strength of their IP and the potential for
> market adoption. They also have a dementia and Alzheimer's test in
> the works - same technology & form factor - pin prick blood sample
> onto a slide, into a sensor to detect the indicative bio markers.
>
>
>
> If you'd like to learn more I can connect you with a board member
> and/or the CEO. I am under NDA, so I cannot share investor docs at this
point.
>
>
>
> Safe travels home and I look forward to the continued dialog.
>
>
>
> All the best,
>
>
>
> Neil
>
>
>
>
>
>
>
>
>
> Neil Callahan
>
> Rosemont Seneca Partners
>
> 401 Greenwich Street, Suite 300
>
> New York, New York 10013
>
> 917-945-9516 (m)
>
> 866-749-8879 (f)
>
> www.rosemontsenecatech.com
>
> Confidentiality Warning: This e-mail contains information intended
> only for the use of the individual or entity named above. If the
> reader of this e-mail is not the intended recipient or the employee or
> agent responsible for delivering it to the intended recipient, any
> dissemination, publication or copying of this e-mail is strictly
> prohibited. The sender does not accept any responsibility for any
> loss, disruption or damage to your data or computer system that may
> occur while using data contained in, or transmitted with, this
> e-mail.If you have received this e-mail in error, please immediately
> notify us by return e-mail. Thank you
>
>